BridgeBio Oncology Therapeutics (BBOT) Receivables (2024 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Receivables of $146000.0 for Q1 2026, down 62.18% sequentially from $386000.0 in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Receivables (2024 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Receivables for 3 years, with the latest figure at $146000.0 in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $146000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146000.0 (changed N/A YoY) and the FY2025 annual result came in at $386000.0, up 376.54% from the prior year.
Receivables fell to $146000.0 in Q1 2026 per BBOT's latest filing, from $386000.0 in the prior quarter.
Over five years, Receivables peaked at $386000.0 in Q4 2025 and troughed at $81000.0 in Q4 2024.
A 3-year average of $204333.3 and a median of $146000.0 in 2026 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 376.54% in 2025, down 376.54% in 2025.
Over 3 years, Receivables stood at $81000.0 in 2024, then surged by 376.54% to $386000.0 in 2025, then plunged by 62.18% to $146000.0 in 2026.
According to Business Quant data, Receivables over the past three periods registered $146000.0, $386000.0, and $81000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-	661,000.00

Download Data